ПСОРИАТИЧЕСКАЯ ЭРИТРОДЕРМИЯ И РЕККУРЕНТНОЕ ДЕПРЕССИВНОЕ РАССТРОЙСТВО, ЭФФЕКТИВНОСТЬ ИНГИБИТОРА ИЛ-23 ГУСЕЛЬКУМАБА
Клинический случай
Дата публикации: ноября 9, 2024
Ключевые слова
псориаз
псориатическая эритродермия
депрессия
гуселькумаб
псориатическая эритродермия
депрессия
гуселькумаб
Аннотация
Депрессия и тревога являются одними из наиболее частых сопутствующих псориазу психических нарушений, оказывающих значительное влияние на качество жизни этих больных и ухудшающих прогноз течения дерматоза. При несвоевременном и неадекватном лечении псориаза увеличивается риск развития тревожно-аффективной патологии, что, в свою очередь, усугубляет течение псориаза. Наиболее тяжелой формой псориаза является псориатическая эритродермия, с поражением до 90% площади поверхности кожи. Несмотря на то, что псориатическая эритродермия относится к тяжелой форме кожного заболевания, подобные осложнения являются редкостью, с чем связаны единичные исследования и публикации, посвященные проблеме эффективности применения системной биологической терапии в этой группе больных. Данные по эффективности и безопасности применения ингибитора ИЛ-23 гуселькумаба при псориатичекой эритродермии крайне ограничены. В представленной публикации описан клинический случай пациента с псориатической эритродермией, псориатическим артритом, тяжелым течением псориаза и сопутствующим рекуррентным депрессивным расстройством, получающего лечение генно-инженерной биологической терапии ингибитором ИЛ-23 (гуселькумабом).Литература
1. Круглова Л.С. и др. Пcориаз. Москва. – 2022. – С. 328.[ Kruglova L.S. et al. Pcoriasis. – Moscow. – 2022. – P. 328. In Russian]
2. Hawkes J. E., Chan T. C., Krueger J. G. Psoriasis pathogenesis and the development of novel targeted immune therapies //Journal of Allergy and Clinical Immunology. – 2017. – V. 140. – No. 3. – P. 645-653.
3. Deng Y., Chang C., Lu Q. The inflammatory response in psoriasis: a comprehensive review //Clinical reviews in allergy & immunology. – 2016. – V. 50. – P. 377-389.
4. Langley R. G. B., Krueger G. G., Griffiths C. E. M. Psoriasis: epidemiology, clinical features, and quality of life //Annals of the rheumatic diseases. – 2005. – V. 64. – No. suppl 2. – P. ii18-ii23.
5. Скрипкин Ю. К., Богуш П.Г., Круглова Л.С., Дворников А.С. Новые возможности наружной терапии псориаза //Вестник дерматологии и венерологии. – 2006. – №. 3. – С. 33-36. [Skripkin Yu. K., Bogush P. G., Kruglova L. S., Dvornikov A. S. New possibilities of external therapy of psoriasis // Bulletin of dermatology and venereology. - 2006. - No. 3. - P. 33-36. In Russian]
6. Shao S. et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances //Drugs. – 2020. – V. 80. – No. 6. – P. 525-534.
7. Lo Y., Tsai T. F. Updates on the treatment of erythrodermic psoriasis //Psoriasis: Targets and Therapy. – 2021. – P. 59-73.
8. Foss M. G., Nyckowski T., Steffes W. Erythrodermic psoriasis exacerbated by bupropion //Cureus. – 2021. – V. 13. – No. 10.
9. Potter K. A., Motaparthi K., Schoch J. J. Erythrodermic psoriasis after discontinuation of ixekizumab //JAAD Case Reports. – 2018. – V. 4. – No. 1. – P. 22-23.
10. Matos-Pires E. et al. Erythrodermic psoriasis induced by bupropion //Journal of the European Academy of Dermatology & Venereology. – 2017. – V. 31. – No. 2.
11. Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab //Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. – 2019. – V. 36. – No. 4. – P. 495-497.
12. Круглова Л. С., Переверзина Н. О., Шатохина Е. А. Вопросы применения генно-инженерных препаратов в условиях новой коронавирусной инфекции COVID-19 //Кремлевская медицина. Клинический вестник. – 2020. – №. 2. – С. 36-42.[ Kruglova L. S., Pereverzina N. O., Shatokhina E. A. Issues of the use of genetically engineered drugs in the context of the new coronavirus infection COVID-19 // Kremlin Medicine. Clinical Bulletin. - 2020. - No. 2. - P. 36-42. In Russian]
13. Wittenberg G. M. et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders //Molecular psychiatry. – 2020. – V. 25. – No. 6. – P. 1275-1285.
14. Papp K. A. et al. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis //British Journal of Dermatology. – 2016. – V. 175. – No. 2. – P. 273-286.
15. Kappelmann N. et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions //Molecular psychiatry. – 2018. – V. 23. – No. 2. – P. 335-343.
16.Круглова Л. С. и др. Псориаз и воспалительные заболевания кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов (обзор литературы) //Альманах клинической медицины. – 2019. – Т. 47. – №. 6. – С. 568-578. [Kruglova L. S. et al. Psoriasis and inflammatory bowel diseases: pathogenesis pathways and issues of choosing genetically engineered drugs (literature review) // Almanac of Clinical Medicine. - 2019. - V. 47. - No. 6. - P. 568-578. In Russian]
17. Владимирова И. С. и др. Эффективность терапии больных псориазом с тревожностью и депрессией ингибитором интерлейкина 23 гуселькумабом //Медицинский алфавит. – 2023. – №. 24. – С. 28-35.[Vladimirova I. S. et al. Efficiency of therapy of patients with psoriasis with anxiety and depression with the interleukin 23 inhibitor guselkumab // Medical alphabet. - 2023. - No. 24. - P. 28-35. In Russian]
18.Shao S. et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances //Drugs. – 2020. – V. 80. – No. 6. – P. 525-534.
19.Rosenbach M. et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation //Journal of the American Academy of Dermatology. – 2010. – V. 62. – No. 4. – P. 655-662.
20. Stinco G., Errichetti E. Erythrodermic psoriasis: current and future role of biologicals //BioDrugs. – 2015. – V. 29. – P. 91-101.
21.Green M. S. et al. Infectious complications of erythrodermic psoriasis //Journal of the American Academy of Dermatology. – 1996. – V. 34. – No. 5. – P. 911-914.
22. Yin L. et al. Systemic abnormalities of psoriatic patients: a retrospective study //Clinical, Cosmetic and Investigational Dermatology. – 2016. – P. 443-449.
23.Lo Y., Chiu H. Y., Tsai T. F. Clinical features and genetic polymorphism in Chinese patients with erythrodermic psoriasis in a single dermatologic clinic //Molecular Diagnosis & Therapy. – 2020. – V. 24. – P. 85-93.
24.Singh R. K. et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives //Psoriasis: Targets and Therapy. – 2016. – P. 93-104.
25.Moy A. P. et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis //Jama Dermatology. – 2015. – V. 151. – No. 7. – P. 753-760.
26.Zhang P. et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis //Journal of Huazhong University of Science and Technology [Medical Sciences]. – 2014. – V. 34. – No. 4. – P. 596-601.
27.Li L. F. et al. Serum immunoglobulins in psoriatic erythroderma //Clinical and experimental dermatology. – 2005. – V. 30. – No. 2. – P. 125-127.
28.Napolitano M. et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experience //Journal of the European Academy of Dermatology & Venereology. – 2022. – V. 36. – No. 9.
29.Napolitano M. et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis //Dermatologic Therapy. – 2021. – V. 34. – No. 6. – P. e15120.
30. Patruno C. et al. Dupilumab for the treatment of adult atopic dermatitis in special populations //Journal of Dermatological Treatment. – 2022. – V. 33. – No. 7. – P. 3028-3033.
31. Tracey E. H. et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab //JAAD Case Reports. – 2018. – V. 4. – No. 7. – P. 708-710.
32.Hölsken S. et al. Common fundamentals of psoriasis and depression //Acta Dermato-Venereologica. – 2021. – V. 101. – No. 11.
33.Patel N. et al. Psoriasis, depression, and inflammatory overlap: a review //American Journal of Clinical Dermatology. – 2017. – V. 18. – No. 5. – P. 613-620.
34.Aksoy H. et al. The impact of antipsoriatic treatment on serum pro‐BDNF, BDNF levels, depression, anxiety scores, and quality of life //Dermatologic Therapy. – 2021. – V. 34. – No. 2. – P. e14872.
35.Fleming P. et al. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials //Journal of the European Academy of Dermatology and Venereology. – 2017. – V. 31. – No. 5. – P. 798-807.
36. Timis T. L. et al. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients //Life. – 2023. – V. 13. – No. 5. – P. 1219.
37.Gordon K. B. et al. Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study //Journal of the European Academy of Dermatology and Venereology. – 2018. – V. 32. – No. 11. – P. 1940-1949.
38. Potestio L. et al. Biologics for the management of erythrodermic psoriasis: an updated review //Clinical, Cosmetic and Investigational Dermatology. – 2023. – P. 2045-2059.
39. Sano S. et al. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52‐week, phase 3, multicenter, open-label study //The Journal of Dermatology. – 2018. – V. 45. – No. 5. – P. 529-539.
40.Chiang C. Y., Tsai T. F. Treatment response of patients with erythrodermic psoriasis after switching to guselkumab //Dermatology and Therapy. – 2021. – V. 11. – P. 301-306.
41. Megna M. et al. A case of erythrodermic psoriasis successfully treated with guselkumab //Dermatologic Therapy. – 2020. – V. 33. – No. 2. – P. e13238.
2. Hawkes J. E., Chan T. C., Krueger J. G. Psoriasis pathogenesis and the development of novel targeted immune therapies //Journal of Allergy and Clinical Immunology. – 2017. – V. 140. – No. 3. – P. 645-653.
3. Deng Y., Chang C., Lu Q. The inflammatory response in psoriasis: a comprehensive review //Clinical reviews in allergy & immunology. – 2016. – V. 50. – P. 377-389.
4. Langley R. G. B., Krueger G. G., Griffiths C. E. M. Psoriasis: epidemiology, clinical features, and quality of life //Annals of the rheumatic diseases. – 2005. – V. 64. – No. suppl 2. – P. ii18-ii23.
5. Скрипкин Ю. К., Богуш П.Г., Круглова Л.С., Дворников А.С. Новые возможности наружной терапии псориаза //Вестник дерматологии и венерологии. – 2006. – №. 3. – С. 33-36. [Skripkin Yu. K., Bogush P. G., Kruglova L. S., Dvornikov A. S. New possibilities of external therapy of psoriasis // Bulletin of dermatology and venereology. - 2006. - No. 3. - P. 33-36. In Russian]
6. Shao S. et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances //Drugs. – 2020. – V. 80. – No. 6. – P. 525-534.
7. Lo Y., Tsai T. F. Updates on the treatment of erythrodermic psoriasis //Psoriasis: Targets and Therapy. – 2021. – P. 59-73.
8. Foss M. G., Nyckowski T., Steffes W. Erythrodermic psoriasis exacerbated by bupropion //Cureus. – 2021. – V. 13. – No. 10.
9. Potter K. A., Motaparthi K., Schoch J. J. Erythrodermic psoriasis after discontinuation of ixekizumab //JAAD Case Reports. – 2018. – V. 4. – No. 1. – P. 22-23.
10. Matos-Pires E. et al. Erythrodermic psoriasis induced by bupropion //Journal of the European Academy of Dermatology & Venereology. – 2017. – V. 31. – No. 2.
11. Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab //Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. – 2019. – V. 36. – No. 4. – P. 495-497.
12. Круглова Л. С., Переверзина Н. О., Шатохина Е. А. Вопросы применения генно-инженерных препаратов в условиях новой коронавирусной инфекции COVID-19 //Кремлевская медицина. Клинический вестник. – 2020. – №. 2. – С. 36-42.[ Kruglova L. S., Pereverzina N. O., Shatokhina E. A. Issues of the use of genetically engineered drugs in the context of the new coronavirus infection COVID-19 // Kremlin Medicine. Clinical Bulletin. - 2020. - No. 2. - P. 36-42. In Russian]
13. Wittenberg G. M. et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders //Molecular psychiatry. – 2020. – V. 25. – No. 6. – P. 1275-1285.
14. Papp K. A. et al. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis //British Journal of Dermatology. – 2016. – V. 175. – No. 2. – P. 273-286.
15. Kappelmann N. et al. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions //Molecular psychiatry. – 2018. – V. 23. – No. 2. – P. 335-343.
16.Круглова Л. С. и др. Псориаз и воспалительные заболевания кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов (обзор литературы) //Альманах клинической медицины. – 2019. – Т. 47. – №. 6. – С. 568-578. [Kruglova L. S. et al. Psoriasis and inflammatory bowel diseases: pathogenesis pathways and issues of choosing genetically engineered drugs (literature review) // Almanac of Clinical Medicine. - 2019. - V. 47. - No. 6. - P. 568-578. In Russian]
17. Владимирова И. С. и др. Эффективность терапии больных псориазом с тревожностью и депрессией ингибитором интерлейкина 23 гуселькумабом //Медицинский алфавит. – 2023. – №. 24. – С. 28-35.[Vladimirova I. S. et al. Efficiency of therapy of patients with psoriasis with anxiety and depression with the interleukin 23 inhibitor guselkumab // Medical alphabet. - 2023. - No. 24. - P. 28-35. In Russian]
18.Shao S. et al. Targeted treatment for erythrodermic psoriasis: rationale and recent advances //Drugs. – 2020. – V. 80. – No. 6. – P. 525-534.
19.Rosenbach M. et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation //Journal of the American Academy of Dermatology. – 2010. – V. 62. – No. 4. – P. 655-662.
20. Stinco G., Errichetti E. Erythrodermic psoriasis: current and future role of biologicals //BioDrugs. – 2015. – V. 29. – P. 91-101.
21.Green M. S. et al. Infectious complications of erythrodermic psoriasis //Journal of the American Academy of Dermatology. – 1996. – V. 34. – No. 5. – P. 911-914.
22. Yin L. et al. Systemic abnormalities of psoriatic patients: a retrospective study //Clinical, Cosmetic and Investigational Dermatology. – 2016. – P. 443-449.
23.Lo Y., Chiu H. Y., Tsai T. F. Clinical features and genetic polymorphism in Chinese patients with erythrodermic psoriasis in a single dermatologic clinic //Molecular Diagnosis & Therapy. – 2020. – V. 24. – P. 85-93.
24.Singh R. K. et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives //Psoriasis: Targets and Therapy. – 2016. – P. 93-104.
25.Moy A. P. et al. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis //Jama Dermatology. – 2015. – V. 151. – No. 7. – P. 753-760.
26.Zhang P. et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis //Journal of Huazhong University of Science and Technology [Medical Sciences]. – 2014. – V. 34. – No. 4. – P. 596-601.
27.Li L. F. et al. Serum immunoglobulins in psoriatic erythroderma //Clinical and experimental dermatology. – 2005. – V. 30. – No. 2. – P. 125-127.
28.Napolitano M. et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real‐life experience //Journal of the European Academy of Dermatology & Venereology. – 2022. – V. 36. – No. 9.
29.Napolitano M. et al. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis //Dermatologic Therapy. – 2021. – V. 34. – No. 6. – P. e15120.
30. Patruno C. et al. Dupilumab for the treatment of adult atopic dermatitis in special populations //Journal of Dermatological Treatment. – 2022. – V. 33. – No. 7. – P. 3028-3033.
31. Tracey E. H. et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab //JAAD Case Reports. – 2018. – V. 4. – No. 7. – P. 708-710.
32.Hölsken S. et al. Common fundamentals of psoriasis and depression //Acta Dermato-Venereologica. – 2021. – V. 101. – No. 11.
33.Patel N. et al. Psoriasis, depression, and inflammatory overlap: a review //American Journal of Clinical Dermatology. – 2017. – V. 18. – No. 5. – P. 613-620.
34.Aksoy H. et al. The impact of antipsoriatic treatment on serum pro‐BDNF, BDNF levels, depression, anxiety scores, and quality of life //Dermatologic Therapy. – 2021. – V. 34. – No. 2. – P. e14872.
35.Fleming P. et al. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials //Journal of the European Academy of Dermatology and Venereology. – 2017. – V. 31. – No. 5. – P. 798-807.
36. Timis T. L. et al. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients //Life. – 2023. – V. 13. – No. 5. – P. 1219.
37.Gordon K. B. et al. Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study //Journal of the European Academy of Dermatology and Venereology. – 2018. – V. 32. – No. 11. – P. 1940-1949.
38. Potestio L. et al. Biologics for the management of erythrodermic psoriasis: an updated review //Clinical, Cosmetic and Investigational Dermatology. – 2023. – P. 2045-2059.
39. Sano S. et al. Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52‐week, phase 3, multicenter, open-label study //The Journal of Dermatology. – 2018. – V. 45. – No. 5. – P. 529-539.
40.Chiang C. Y., Tsai T. F. Treatment response of patients with erythrodermic psoriasis after switching to guselkumab //Dermatology and Therapy. – 2021. – V. 11. – P. 301-306.
41. Megna M. et al. A case of erythrodermic psoriasis successfully treated with guselkumab //Dermatologic Therapy. – 2020. – V. 33. – No. 2. – P. e13238.